[Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)].

Abstract

UNLABELLED We evaluated the efficacy and safety of peginterferon alfa-2a [40KD] (Peg-IFNalpha-2a) plus ribavirin in patients with chronic hepatitis C in an open-label programme in a routine clinical setting in Poland. Patients received Peg-IFNalpha-2a 180mg/week plus ribavirin 800-1200 mg/d for 48 weeks. Sustained virological response (SVR) was defined as… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.